

**Date: August 07, 2025**

To, The Manager, Listing Department, <b>National Stock Exchange of India Limited (NSE),</b> Exchange Plaza, C – 1, Block – G, Bandra – Kurla Complex, Bandra (E), Mumbai-400 051.	To, The Department of Corporate Service, <b>BSE Limited,</b> 1 <sup>st</sup> Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400 001.
<b>Symbol – LINCOLN</b>	<b>Scrip Code – 531633</b>

Dear Sir,


**SUB.: OUTCOME OF BOARD MEETING.**

Further to our intimation dated July 28, 2025, pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we would like to inform that the Board of Directors of the Company at its meeting held today i.e. on Thursday, August 07, 2025, have considered/approved/recommended, inter alia, the followings: -

1. The un-audited financial results (standalone and consolidated) of the Company for the quarter ended on June 30, 2025 along with the limited review report from auditors thereon. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of un-audited consolidated financial results for the quarter ended on June 30, 2025. The un-audited financial results (standalone and consolidated) will be available at Company's website at [www.lincolnpharma.com](http://www.lincolnpharma.com). Further, we enclose herewith financial highlights for the aforesaid quarter.
2. Based on the recommendation of the Nomination and Remuneration Committee, Mr. Mahendra G. Patel (DIN:00104706) has been re-appointed as the Managing Director of the Company for a period of 5 (Five) years beginning from October 01, 2025 subject to the approval of the Shareholders of the Company.
3. Based on the recommendation of the Nomination and Remuneration Committee, Mr. Hashmukh I. Patel (DIN: 00104834) has been re-appointed as the Whole Time Director of the Company for a period of 5 (Five) years beginning from October 01, 2025 subject to the approval of the Shareholders of the Company.
4. Based on the recommendation of the Nomination and Remuneration Committee, Mr. Ashish R. Patel (DIN: 01309017) has been re-appointed as the Whole Time Director of the Company for a period of 5 (Five) years beginning from November 14, 2025 subject to the approval of the Shareholders of the Company.
5. Based on the recommendation of the Nomination and Remuneration Committee, Mr. Munjal M. Patel (DIN: 02319308) has been re-appointed as the Whole Time Director of the Company for a period of 5 (Five) years beginning from November 14, 2025 subject to the approval of the Shareholders of the Company.

**Regd. Office :** "Lincoln House", B/h. Satyam Complex, Science City Road, Sola, Ahmedabad-380060, Gujarat, India.  
**Phone :** +91-79-4107 8000 | **CIN** L24230GJ1995PLC024288  
**E-mail :** [info@lincolnpharma.com](mailto:info@lincolnpharma.com) | **Website :** [www.lincolnpharma.com](http://www.lincolnpharma.com)

**Factory :** Trimul Estate, Khatraj, Tal.- Kalol, Dist.- Gandhinagar-382721, Gujarat State, India  
**Phone :** +91-79-4913 5000 | **E-mail :** [khatraj@lincolnpharma.com](mailto:khatraj@lincolnpharma.com)





6. The Appointment of M/s Ankit Sethi & Associates, Peer Reviewed Practicing Company Secretary proprietorship firm (COP No: 11089), as Secretarial Auditor of the Company, pursuant to the provisions of Regulation 24A of Listing Regulations, as amended ("SEBI Listing Regulations") and Section 204 of the Companies Act, 2013 read with Rule 8 of the Companies (Meetings of Board and its powers) Rules, 2014 and based on the recommendation of the Audit Committee and the Directors of the Company, for undertaking the Secretarial Audit of the Company for the one term of five (5) Consecutive years, for the Financial Year w.e.f 01st April, 2025 to 31st March, 2030, subject to Shareholders' Approval in ensuing Annual General Meeting of the Company.

Meeting of the Board of Directors commenced at 11:00 and concluded at 12:45 P.M.  
Kindly take the same on your records.

Thanking you,  
Yours faithfully,

**For Lincoln Pharmaceuticals Limited**



**Trusha Shah**  
**Company Secretary & Compliance Officer**  
Encl: A/a

# LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,

Website: www.lincolnpharma.com, E-Mail: investor@lincolnpharma.com

## Statement of Standalone Un-Audited Financial Results for the Quarter Ended on 30-June-2025.

Sr. No.	Particulars	Quarter Ended			(₹ in Lakhs)
		30/06/2025	31/03/2025	30/06/2024	Year Ended
		(Un-Audited)	Refer No. 3	(Un-Audited)	31/03/2025 (Audited)
<b>1</b>	<b>Income</b>				
	A) Revenue From Operations	15,406.67	16,818.31	14,728.18	62,323.01
	B) Other Income	1,527.17	(687.97)	1,040.92	2,247.71
	<b>Total Income (1)</b>	<b>16,933.84</b>	<b>16,130.34</b>	<b>15,769.10</b>	<b>64,570.72</b>
<b>2</b>	<b>Expenses</b>				
	A) Cost of Material Consumed	6,096.93	5,393.05	5,274.56	21,393.84
	B) Purchase of Stock-In-Trade	1,583.06	1,474.64	1,333.07	6,854.12
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	(741.56)	1,147.51	416.23	884.00
	D) Employee Benefits Expenses	3,175.68	2,762.03	2,901.99	11,245.42
	E) Finance Costs	20.98	36.67	43.91	188.27
	F) Depreciation and Amortisation Expense	347.72	322.60	322.43	1,289.90
	G) Other Expenses	2,912.11	3,369.19	2,529.12	11,796.31
	<b>Total Expenses (2)</b>	<b>13,394.92</b>	<b>14,505.69</b>	<b>12,821.31</b>	<b>53,651.86</b>
<b>3</b>	<b>Profit / (Loss) Before Exceptional Items &amp; Tax (1-2)</b>	<b>3,538.92</b>	<b>1,624.65</b>	<b>2,947.79</b>	<b>10,918.86</b>
4	Exceptional Items	Nil	Nil	Nil	Nil
<b>5</b>	<b>Profit / (Loss) after Exceptional items but Before Tax (3-4)</b>	<b>3,538.92</b>	<b>1,624.65</b>	<b>2,947.79</b>	<b>10,918.86</b>
6	Tax Expense				
	A) Current Tax	412.30	669.20	551.30	2,487.20
	B) Deferred Tax	359.10	(197.94)	29.32	151.53
	C) Short / (Excess) Tax Provision	Nil	(4.11)	Nil	45.49
<b>7</b>	<b>Net Profit / (Loss) For The Period (5-6)</b>	<b>2,767.52</b>	<b>1,157.50</b>	<b>2,367.17</b>	<b>8,234.64</b>
8	Other Comprehensive Income (Net Of Tax)				
	Items that will not be reclassified to subsequently to profit and loss	2.29	4.59	1.53	9.17
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil
<b>9</b>	<b>Total Comprehensive Income</b>	<b>2,769.81</b>	<b>1,162.09</b>	<b>2,368.70</b>	<b>8,243.81</b>
10	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,002.97	2,002.97	2,002.97	2,002.97
11	Other Equity				65,163.89
<b>12</b>	<b>Earnings Per Share (of Rs. 10/- Each) (Not Annualised)</b>				
	(a) Basic	13.82	5.78	11.82	41.11
	(b) Diluted	13.82	5.78	11.82	41.11

### NOTES:

- The above unaudited standalone financial results of the Company for the quarter ended June 30, 2025 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, August 07, 2025. The auditor have carried out an limited review of the said financial results.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- The figures for the quarter ended March 31, 2025 is the balancing figure between audited figures in respect of the full financial year and for the period upto the end of the third quarter of relevant financial year.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.

For Lincoln Pharmaceuticals Limited



Place: Ahmedabad  
Date: August 07, 2025

*Mahendra G. Patel*  
Mahendra G. Patel  
Managing Director  
DIN: 00104706

# SAMIR M. SHAH & ASSOCIATES

## Chartered Accountants

"Heaven", 8, Western Park Society, Nr. TRP Mall,  
Bopal, Ahmedabad – 380058

Phone : +91- 76220 12032

E-mail : samir@smshah.co.in

**Limited Review Report on standalone un-audited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

To the Board of Directors of,  
Lincoln Pharmaceuticals Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Lincoln Pharmaceuticals Limited ("the Company") having its Registered Office at "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola, Ahmedabad – 380060, Gujarat for the quarter ended June 30, 2025. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

The Statement includes the results for the quarter ended 31<sup>st</sup> March 2025 being the derived figures between the audited figures in respect of the full financial year ended 31<sup>st</sup> March 2025 and the unaudited year-to-date figures upto 31<sup>st</sup> December 2024 which were subjected to a limited review.

**2. Management's Responsibility for the statement:**

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

**3. Auditor's Responsibility:**

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



**4. Conclusion:**

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad

Date: 07/08/2025

For, Samir M Shah & Associates  
Chartered Accountants

(Firm's Registration No. 122377W)

*Samir*  
(Samir M. Shah)

Partner

[Memb. No. 111052]

UDIN : 25111052BMJXCW5009



# LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,

Website: www.lincolnpharma.com, E-Mail: investor@lincolnpharma.com

## Statement of Consolidated Un-Audited Financial Results for the Quarter Ended on 30-June-2025.

Sr. No.	Particulars	Quarter Ended			(₹ in Lakhs)
		30/06/2025	31/03/2025	30/06/2024	Year Ended
		(Un-Audited)	Refer No. 3	(Un-Audited)	31/03/2025
<b>1</b>	<b>Income</b>				
	A) Revenue From Operations	15,406.67	16,818.31	14,728.18	62,323.01
	B) Other Income	1,527.17	(687.97)	1,040.92	2,247.71
	<b>Total Income (1)</b>	<b>16,933.84</b>	<b>16,130.34</b>	<b>15,769.10</b>	<b>64,570.72</b>
<b>2</b>	<b>Expenses</b>				
	A) Cost of Material Consumed	6,096.93	5,393.05	5,274.56	21,393.84
	B) Purchase of Stock-In-Trade	1,583.06	1,474.64	1,333.07	6,854.12
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	(741.56)	1,147.51	416.23	884.00
	D) Employee Benefits Expenses	3,175.68	2,762.03	2,901.99	11,245.42
	E) Finance Costs	20.98	36.68	43.91	188.28
	F) Depreciation and Amortisation Expense	347.72	322.60	322.43	1,289.90
	G) Other Expenses	2,912.11	3,369.18	2,529.12	11,796.30
	<b>Total Expenses (2)</b>	<b>13,394.92</b>	<b>14,505.69</b>	<b>12,821.31</b>	<b>53,651.86</b>
<b>3</b>	<b>Profit / (Loss) Before Exceptional Items &amp; Tax (1-2)</b>	<b>3,538.92</b>	<b>1,624.65</b>	<b>2,947.79</b>	<b>10,918.86</b>
<b>4</b>	Exceptional Items	Nil	Nil	Nil	Nil
<b>5</b>	<b>Profit / (Loss) after Exceptional items but Before Tax (3-4)</b>	<b>3,538.92</b>	<b>1,624.65</b>	<b>2,947.79</b>	<b>10,918.86</b>
<b>6</b>	Tax Expense				
	A) Current Tax	412.30	669.20	551.30	2,487.20
	B) Deferred Tax	359.10	(197.94)	29.32	151.53
	C) Short / (Excess) Tax Provision	Nil	(4.11)	Nil	45.49
<b>7</b>	<b>Net Profit / (Loss) For The Period (5-6)</b>	<b>2,767.52</b>	<b>1,157.50</b>	<b>2,367.17</b>	<b>8,234.64</b>
<b>8</b>	Other Comprehensive Income (Net Of Tax)				
	Items that will not be reclassified to subsequently to profit and loss	2.29	4.59	1.53	9.17
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil
<b>9</b>	<b>Total Comprehensive Income</b>	<b>2,769.81</b>	<b>1,162.09</b>	<b>2,368.70</b>	<b>8,243.81</b>
<b>10</b>	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,002.97	2,002.97	2,002.97	2,002.97
<b>11</b>	Other Equity				65,163.89
<b>12</b>	<b>Earnings Per Share (of Rs. 10/- Each) (Not Annualised)</b>				
	(a) Basic	13.82	5.78	11.82	41.11
	(b) Diluted	13.82	5.78	11.82	41.11

### NOTES:

- The above unaudited consolidated financial results of the Company for the quarter ended June 30, 2025 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, August 07, 2025. The auditor have carried out an limited review of the said financial results.
- This financial statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- The figures for the quarter ended March 31, 2025 is the balancing figure between audited figures in respect of the full financial year and for the period upto the end of the third quarter of relevant financial year.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.
- Consolidated Results includes results of its subsidiary namely Zullinc Healthcare LLP.

For Lincoln Pharmaceuticals Limited



*Mahendra G. Patel*

Mahendra G. Patel  
Managing Director  
DIN: 00104706

Place: Ahmedabad  
Date: August 07, 2025

# **SAMIR M. SHAH & ASSOCIATES**

## **Chartered Accountants**

"Heaven", 8, Western Park Society, Nr. TRP Mall,  
Bopal, Ahmedabad – 380058

Phone : +91- 76220 12032

E-mail : samlr@smsshah.co.in

**Limited Review Report on consolidated un-audited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

To the Board of Directors of,  
**Lincoln Pharmaceuticals Limited,**

1. We have reviewed the accompanying statement of consolidated unaudited financial results of **Lincoln Pharmaceuticals Limited**("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended(the "Listing Regulations").

The Statement includes the results for the quarter ended 31st March 2025 being the derived figures between the audited figures in respect of the full financial year ended 31st March 2025 and the unaudited year-to-date figures up to 31st December 2024 which were subjected to a limited review.

2. **Management's Responsibility for the statement:**

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. **Auditor's Responsibility:**

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

- |                                    |   |                                 |
|------------------------------------|---|---------------------------------|
| A. Lincoln Pharmaceuticals Limited | - | Parent Company                  |
| B. Zullinc Healthcare LLP          | - | Wholly-Owned Subsidiary Company |

5. **Conclusion:**

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. **Other Matter:**

We did not review the interim financial information of one subsidiary included in the consolidated unaudited financial results, whose interim financial information reflects total revenues of Rs.Nil Lakhs, total net loss after tax of Rs.Nil Lakhs, for the quarter ended June 30, 2025, as considered in the statement. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

According to the information and explanations given to us by the Management, above financial results are not material to the Group. Our conclusion on the Statement, in so far as it relates to the amounts included in respect of these subsidiaries, is based solely on the information and explanations given to us by the Management.

Our conclusion on the statement in respect of matters stated in para 6 above is not modified.

Place: Ahmedabad

Date: 07/08/2025

For, Samir M Shah & Associates

Chartered Accountants


(Firm's Registration No. 122377W)

  
(Samir M. Shah)

Partner

[Memb. No. 111052]

UDIN: 25111052BMJXCX6366



Media Release

## Lincoln Pharmaceuticals Ltd Reports Standalone Net Profit of Rs. 27.70 crore in QI FY26, growth of 16.93% Y-o-Y

### Business Highlights:

- Total Income for QI FY26 rise 7.39% Y-o-Y to Rs. 169.34 crore; EBITDA was up 17.91% Y-o-Y to Rs. 39.08 crore.
- FII's steadily raised holding in the company to 5.13% as of June 2025 from 3.95% as on June 2024
- Aims to achieve a 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments
- Company is targeting revenue of Rs 1,000 crore in next 3 years

### Financial Highlights (Standalone)

(Amount in Cr except EPS)

	QI FY26	QI FY25	Y-o-Y	FY25	FY24	Y-o-Y
<b>Total Income</b>	<b>169.34</b>	157.69	<b>7.39%</b>	645.71	614.97	5.00%
EBITDA	<b>39.08</b>	33.14	<b>17.92%</b>	123.97	134.33	-7.71%
PBT	<b>35.39</b>	29.48	<b>20.05%</b>	109.19	122.24	-10.68%
<b>Net Profit</b>	<b>27.70</b>	23.69	<b>16.93%</b>	82.44	93.37	-11.71%
E.P.S (Rs.)	<b>13.82</b>	11.82	<b>16.92%</b>	41.11	46.58	-11.74%

**Ahmedabad, August 7, 2025:** Lincoln Pharmaceuticals Ltd (BSE: 531633, NSE: LINCOLN), one of India's leading healthcare companies has reported its operational and financial performance for QI FY 2025-26 ended 30th June 2025. Company has reported a standalone net profit of Rs. 27.70 crore for the QI FY 2025-26 as compared to the net profit of Rs. 23.69 crore reported in QI FY 2024-25, growth of 16.93% Y-o-Y. Total income for the quarter ended June 2025 was reported at Rs. 169.34 crore, higher by 7.39% Y-o-Y over total income of Rs. 157.69 crore in QI FY2024-25. EBITDA for QI FY26 was reported at Rs. 39.08 crore as compared to EBITDA of Rs. 33.14 crore in QI FY25, growth of 17.92% Y-o-Y. EPS for QI FY26 was at Rs. 13.82 per share.

Company is targeting a revenue of Rs. 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets. This goal is part of a broader strategy to achieve a 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments. Company is committed to expanding its global footprint while meeting diverse healthcare needs. Foreign Institutional Investors (FIIs) have steadily increased their stake in the company, rising from 3.95% in June 2024 to 5.13% as of June 2025.

Speaking on the financial performance and future plans, **Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited**, said

- Many countries had been added for the Cephalosporin plant products and product registration will be offered from these countries.




- During the Q1 FY26 company had started Bulk Drug Manufacturing Plant. For which product approval had been received for 10 products and others are under process. At present company had plan to invest Rs. 4 Cr for this plant from internal accruals of the company.

The company's growth strategy focuses on expanding its global footprint by registering new products for export, enhancing domestic market presence, and utilizing state-of-the-art manufacturing facilities that meet international standards. With a strong foundation in the acute segment, the company is now building a robust portfolio in lifestyle and chronic segments, particularly in women's healthcare and dermatology. Supported by healthy cash accruals, no-term debt, and strong return ratios, the company's liquidity remains solid.

Company remains focused on strengthening its presence in regulated and semi-regulated markets. It currently exports to 60+ countries across East and West Africa, Central and North America, Latin America, and Southeast Asia. Company aims to expand this footprint to 90 countries over next 2-3 years. With recent entry into the Canadian market and approvals from TGA - Australia and EU GMP, the company is poised for further global expansion.

Company has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, TGA, WHO-GMP; ISO-9001:2015, ISO-14001:2015 and ISO-45001:2018. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filed 25 plus patent applications and is awarded with seven patents. Company showcases its dedication to innovation and growth through a robust portfolio boasting over 1,700 registered products, with 700 more in development.





**Lincoln Pharmaceuticals Limited: <https://www.lincolnpharma.com/>**

**Providing Affordable and Innovative medicines for healthier lives.**

Lincoln Pharmaceuticals Limited is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has over 1,700 registered products and another 700 in pipeline. The company has its strong presence in Domestic market with good strength of own field force and also exports to more than 60 Countries.

Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with vision for nurturing innovations and bringing them to Indian patients at affordable cost to create **“Healthcare for All”**.

Lincoln Pharma has two state-of-the-art manufacturing facility units at Khatraj in Ahmedabad and Mehsana, Gujarat. Company's manufacturing facilities comply with stringent international quality and compliance norms and certified by EUGMP, TGA, WHO-GMP; ISO-9001:2015, ISO-14001:2015 and ISO-45001:2018, other ROW and emerging market regulatory approvals. Company is engaged in manufacturing of pharma formulations like Tablets, Capsules, Injectables, Syrups, Ointments, etc.

Company's key strength is embedded in its cutting-edge research and development capabilities. The company has a strong R&D team including 30 plus scientists. It has filled 25 plus patent applications and is awarded seven patents. R&D facility of the company is recognised by the Department of Scientific and Technology, Government of India and furnished with state-of-the-art devices and equipment for internal physical, chemical and microbiological analysis of all products.

Company has a strong presence in the domestic market nationally with a dedicated field force of over 600. Company has a wide national distribution network through 21+ Super Stockist in 26 states across India.

Going green, company has also set up a new Solar Plant at Mehsana factory and Khatraj factory in addition to at Radhanpur, Gujarat and two windmills. This way we are nearly a 100% green renewable energy consuming company resulting significant saving in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization.

**For further information please contact:**

**Gopal Modi**  
DSNN Consultancy  
9099030184  
[gopal@dsnnconsultancy.com](mailto:gopal@dsnnconsultancy.com)



**Darshit A. Shah (CFO)**  
Lincoln Pharmaceuticals Ltd  
+91-79-4107-8048  
[darshit@lincolnpharma.com](mailto:darshit@lincolnpharma.com)